Teneria: 5th Approved DPP4-Inhibitor Is Purely Domestic

Orally administered anti-diabetes drug Teneria (teneligliptin) was approved for manufacture June 29.

Orally administered anti-diabetes drug Teneria (teneligliptin) was approved for manufacture June 29. The drug is suitable for type-2 diabetes when a special diet and exercise treatment, and additional sulphonylurea or thiazolidinedione treatment is not sufficient. The main characteristics of the drug are sustainable glycemic control through once-a-day oral intake and ease of use for patients with low renal excretion rates or impaired renal functions. This DPP4-inhibitor is also purely domestic, as it is developed and produced in Japan, and is based on data collected from Japanese people. (Click Here For More – Japanese Language)

“Teneria: 5th Japanese “Purely Domestic” DPP4-Inhibitor” -medical.nikkeibp.co.jp (7/27/2012)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By 

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By 

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

More from Focus On Asia